Oncology

This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.

Ochsner Health System’s brings early-stage clinical trials to the Gulf South region.

Here are the top 3 new approvals from FDA.

New cancer developments and research can be challenging to sort through. Here are four misconceptions about cancer that you should know.

A stepwise approach can be best. Here are seven rules to follow.

Payers struggle to determine the appropriate criteria for covering innovative treatments and providers want to increase patient access. Patients’ lives can hang in the balance.

Onboarding new oncology patients can be a delicate process to help them prepare for their care journey. Here are the first steps.

While promising new options keep entering the scene, high costs can be problematic to patients and healthcare organizations. Here are some ways to cope.

The latest lymphoma research continues to bring new hope for patents, families and care providers. In looking at such advances, here are four things to know.

Cancer is one of the top deadliest diseases in the world and can be difficult to treat. We want to hear from you about your current challenges and what you think about future prospects in cancer therapy.

Medical malpractice companies partner to provide a detailed analysis of breast cancer medical malpractice claims. The findings may surprise you.

Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.

If it's true that a picture is worth a thousand words, the same can be said for numbers.  For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.

Researchers and scientists continue to develop and test new treatments for these fatal conditions. Here’s a look at some major developments in these areas.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Two oncology practices have wish list items for payers. Find out what they are.

In this era of precision oncology and targeted therapies for cancer, it’s even more important to include different populations when doing clinical trials. Here are three effective strategies.

Researchers say two new related study findings represent a potential new way to identify pancreatic cancer at an earlier stage. Read more.

FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.

Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.

A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.

What does team-based cancer care done right look like? Here are two real-word models worth emulating.

A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.

A new study investigates whether PET scans can help guide treatment in patients with aggressive non-Hodgkin lymphomas.

A lymphoma expert from the Allegheny Health Network Cancer Institute reveals the status of current and pipeline lymphoma treatments and the three new treatments healthcare executives need to keep on their radar.

New Cardinal Health Specialty Solutions research shares inside information about oncologists’ views about targeted therapies.

The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.

FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.

The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.